Novartis
Neurodegenerative market to be worth $45 billion by 2022
December 12, 2016Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative
Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …
Novartis’ drug doubly effective as chemotherapy for treating lung cancer
December 8, 2016NSCLC, Novartis, chemotherapy
Novartis have released that its drug, Zykadia, in Phase III trials, was twice as effective at slowing progression in advanced …
Novartis posts 82% remission rate in CAR T paediatric study
December 5, 2016Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric
Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …
Actinium snatches up ex-Novartis clinical manager
November 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actinium, Novartis, appointment
Actinium Pharmaceuticals has appointed Gregory Bergonio to the position of director of Clinical Operations, where he will first guide the …
Novartis in $665 million deal for Selexys
November 21, 2016Sales and Marketing Novartis, SelG1, selexys
Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …
Amgen boosted in race to market for migraine drug
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III
Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
Novartis reportedly in talks to acquire Amneal in $8 billion deal
November 15, 2016Manufacturing and Production, Sales and Marketing Amneal pharmaceuticals, Novartis, joe jimenez
Novartis are said to be eyeing a deal for Amneal pharmaceuticals in order to bolster its Sandoz generics business. Bloomsberg …
Novartis reveals positive three-year efficacy data for psoriatic arthritis drug
November 15, 2016Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis
Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …
Experimental Novartis leukaemia and mastocytosis drug gets FDA Priority Review
November 14, 2016Research and Development, Sales and Marketing FDA, Novartis, acute myeloid leukaemia
The US FDA has granted Priority Review status to Novartis’ experimental drug PKC412 (midostaurin) as a treatment for advanced systemic …
Pfizer’s breast cancer drug gets EU approval
November 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Novartis, Pfizer, ibrance
Pfizer is celebrating the approval by the European Union of its breast cancer drug Ibrance, following a positive recommendation from …
Novartis breast cancer drug secures FDA fast-track status
November 1, 2016Manufacturing and Production, Sales and Marketing Novartis, Pfizer, ibrance, letrozole, riboclib
Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …
Novartis elects new MD for UK plant
October 28, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, appointment
Novartis has named Cynthia Chiaramitara as managing director of its plant in Grimsby, UK. She will take on the role …
Novartis rides out fiscal hardship to beat Q3 forecasts
October 25, 2016Manufacturing and Production, Sales and Marketing Entresto, Gleevec, Novartis
Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …
Novartis in collaboration deal worth potential $1.2 billion with Cerulean
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerulean, NDC, Novartis
Novartis has signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on milestones met, to co-develop nanoparticle-drug …
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
